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Dapagliflozin stimulates glucagon 
secretion at high glucose: 
experiments and mathematical 
simulations of human A-cells
Morten Gram Pedersen1, Ingela Ahlstedt2, Mickaël F. El Hachmane2 & Sven O. Göpel2
Glucagon is one of the main regulators of blood glucose levels and dysfunctional stimulus secretion 
coupling in pancreatic A-cells is believed to be an important factor during development of diabetes. 
However, regulation of glucagon secretion is poorly understood. Recently it has been shown that 
Na+/glucose co-transporter (SGLT) inhibitors used for the treatment of diabetes increase glucagon 
levels in man. Here, we show experimentally that the SGLT2 inhibitor dapagliflozin increases 
glucagon secretion at high glucose levels both in human and mouse islets, but has little effect at low 
glucose concentrations. Because glucagon secretion is regulated by electrical activity we developed 
a mathematical model of A-cell electrical activity based on published data from human A-cells. With 
operating SGLT2, simulated glucose application leads to cell depolarization and inactivation of the 
voltage-gated ion channels carrying the action potential, and hence to reduce action potential height. 
According to our model, inhibition of SGLT2 reduces glucose-induced depolarization via electrical 
mechanisms. We suggest that blocking SGLTs partly relieves glucose suppression of glucagon secretion 
by allowing full-scale action potentials to develop. Based on our simulations we propose that SGLT2 is 
a glucose sensor and actively contributes to regulation of glucagon levels in humans which has clinical 
implications.
Insulin and glucagon, released from pancreatic B- and A-cells respectively, are the main regulators of the blood 
glucose concentration. Insulin is released at high blood glucose levels and directly triggers uptake of the sugar 
into fat and skeletal muscle tissue and promotes glucose uptake into the liver by stimulating glycogenesis. The 
significance of loss of B-cell secretory capacity for the development of diabetes is well established and the term 
islet function is often used synonymously with the ability of B-cells to secrete insulin. However, data demonstrat-
ing the contribution of disturbed glucagon secretion to disease development is accumulating. Diabetic subjects 
suffer from elevated glucagon levels at normal and high glucose concentrations1,2. Since glucagon triggers glucose 
release from the liver, too high resting glucagon levels will worsen the situation in diabetic subjects by raising the 
blood glucose levels even more. In addition, type-1 and type-2 diabetics approaching later stages of the disease 
often lack the ability to respond to hypoglycemia with increased glucagon secretion, leaving them without pro-
tection against potentially life threatening low blood sugar levels3–7. The point can be made that malfunctioning 
A-cell stimulus secretion coupling is the driver for hyperglycemia and loss of islet cell function: Upon continuous 
glucose infusion rats become hyperglycemic after 6 days. This coincides with glucagon hypersecretion whereas 
insulin release is still unaffected and no signs of insulin resistance are apparent8. In addition, B-cell ablation by 
application of streptocotozin, a widely used diabetes model, does not lead to hyperglycemia in glucagon receptor 
knock out animals (GlgRKo)9. However, streptozotocin treated GlgRKo animals become diabetic when the recep-
tor is re-inserted by adenovirus transfection. Although evidence for the physiological importance of glucagon 
is constantly increasing, regulation of its release is much less understood than stimulus-secretion coupling in 
B-cells.
The regulation of glucagon secretion is subject of intense debate and several mechanisms have been pro-
posed. Paracrine regulation by insulin10–13 or zinc14 released from B-cells, or by somatostatin released from 
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D-cells15, have been proposed to play a dominant role. However, glucagon release is strongly inhibited by glu-
cose concentrations too low to have a substantial effect on insulin secretion16 and glucose remains inhibitory on 
glucagon release even after blockage of somatostatin signaling16,17. Clearly, glucagon secretion is regulated by 
several mechanisms but glucose must have a direct effect on A-cells. A-cell inherent glucose sensing has been 
proposed to depend on store operated channels18 or on ATP-sensitive K+ (KATP-) channels19,20. Secretion from 
A-cells is, as in neuroendocrine cells, triggered by increases in the intracellular Ca2+-concentration, which in 
turn depends on action potential firing. In mouse A-cells Na+- and Ca2+-current dependent electrical activity 
is directly regulated by KATP-channel activity19,20, and we proposed that increasing the glucose concentration 
leads to closure of KATP-channels, A-cell plasma membrane depolarization and subsequent inactivation of the 
voltage-dependent Na+ and Ca2+-channels, thus reducing the amplitude of A-cell action potentials21. The inhib-
itory effect of KATP-channel closure on electrical activity and glucagon secretion was later confirmed in human 
A-cells22. Nevertheless, closure of KATP-channels alone will not depolarize the cell membrane up to the threshold 
of action potential initiation unless inward background currents are present. Therefore we predicted a none selec-
tive background conductance in our mathematical mouse A-cell model21.
Recently, SGLT blockers have been developed for the treatment of diabetes. SGLTs are a family of Na+/glucose 
symporters expressed in the kidney, and SGLT blockers reduce blood glucose levels by inhibiting renal glucose 
reabsorption. SGLTs utilize the electrochemical gradient of sodium to transport glucose into the cell and gener-
ate thus an inward current that may lead to depolarization of the cell membrane. It has been demonstrated that 
two chemically unrelated SGLT2 blockers, dapagliflozin and empagliflozin, despite their glucose lowering effect, 
increase plasma glucagon levels and raise endogenous glucose production in diabetic subjects23,24. Further, SGLT2 
is expressed in pancreatic A-cells, and its inhibition triggers glucagon release25. Here we confirm that dapagli-
flozin directly affects glucagon secretion and investigate the cellular mechanisms underlying these findings with 
a mathematical model of A-cell electrical activity developed from human data, potentially explaining the clinical 
observations in diabetic patients.
Results
Glucagon secretion from pancreatic islets. Dapagliflozin and empagliflozin, two chemically unrelated 
SGLT-blockers, both increase plasma glucagon levels in diabetic patients23,24. We therefore tested the effects of 
10 nM dapagliflozin on glucagon secretion in human pancreatic islets (Fig. 1, left). Dapaglifozin is a competitive 
inhibitor with in vitro IC50 value at 2.5 mM glucose of ~1.5 nM, which increases at higher glucose concentrations 
(unpublished results). A daily dose of 10 mg results in 24–240 nM blood concentration and taking ~93% protein 
binding into account yields 1.7–17 nM free dapagliflozin26. The dose used here thus reflects therapeutic use of the 
drug.
Raising the glucose concentration from 1 to 11 mM lowered glucagon release to 13% (Fig. 1; p < 0.001 by 
linear mixed-effects statistical modeling of log-transformed data, see Methods). 10 nM dapagliflozin strongly 
reduced release-inhibition by 11 mM glucose to 29% of control (p = 0.016), and showed a trend towards an inhib-
itory effect on secretion at low glucose (51% of control, p = 0.050). Similar results were obtained in mouse islets 
Figure 1. Effect of dapagliflozin (10 nM) on glucagon secretion from human and mouse islets at different 
glucose concentrations. The figure shows estimates from linear mixed-effects statistical modeling with error 
bars indicating standard errors. For each islet preparation (i.e., each individual or animal) 6–8 groups of size-
matched islets were tested for each indicated condition from 3 donors for human data, and from 29 (1 mM 
glucose), 11 (6 mM glucose) or 18 (11 mM glucose) animals for mouse data.
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(Fig. 1, right): at 11 mM glucose, dapagliflozin raised glucagon release from 18% to 32% of control (p = 0.002), 
while the effect of dapagliflozin addition was minor at 1 mM glucose (84% of control, p = 0.301). At the inter-
mediate glucose concentration of 6 mM, glucagon secretion was estimated to be 24% and 30% of control in the 
absence or presence of dapagliflozin, respectively (p = 0.298).
Mathematical modeling. Having established that SGLT2 inhibition stimulates glucagon release at high 
glucose, we aimed at obtaining mechanistic insight using mathematical modeling. For this purpose, we sim-
ulated each individual current for which data from human A-cells were available. Our model thus includes 
voltage-dependent Na+, T-, L- and P/Q-type Ca2+, as well as A-type and delayed-rectifier K+ channels, in addi-
tion to KATP channels. Parameters where chosen to generate currents as close to experimental data22 as possible, 
and then adjusted minimally in order to obtain stable electrical activity in the whole-cell model. Since A-cells 
express SGLTs25, we also added a mathematical model of SGLT2 co-transport and the related electrogenic current, 
based on the model originally formulated for rabbit SGLT1 by Parent et al.27, and subsequent modifications to 
account for differences between rabbit and humans28, and between SGLT1 and SGLT229.
The SGLT2 current carried by Na+ co-transport is a depolarizing current, as is the SGLT1 current responsible 
for initiating electrical activity and GLP-1 release from intestinal L-cells30,31. It is thus counterintuitive how the 
depolarizing SGLT2 current can lower glucagon secretion from A-cells. However, blocking the hyperpolarizing 
current through KATP channels with tolbutamide also inhibits glucagon release both in mouse19 and human22 
islets, in contrast to its stimulating effect on insulin release. The particular properties of A-cell electrophysiol-
ogy have been suggested to underlie the inhibitory effect of tolbutamide in A-cells, where tolbutamide applica-
tion depolarizes the cell but lowers action potential amplitude19,20,32. Mathematical modeling has shown that the 
electrophysiological properties of mouse A-cells can account for the reduction of action potential amplitude in 
response to KATP channel closure21,33, and that this leads to inhibition of glucagon secretion due to reduced open 
probability of P/Q-type Ca2+ channels34.
Therefore, we speculated that in pancreatic A-cells SGLT2 activation might have an effect similar to KATP 
channel blockage. Our simulations predict that AP firing is reduced in frequency and amplitude when the exter-
nal glucose concentration is increased from 1 to 6 or 11 mM (Fig. 2), in agreement with membrane potential 
recordings from mouse A-cells32. Simulating addition of dapagliflozin in the presence of high glucose reverts 
action potential height and frequency almost back to what was observed at low glucose alone. Since glucagon 
secretion is highly dependent on the action potential height22,34,35, this simulation suggests that SGLT2 blockers 
stimulate glucagon secretion at high glucose concentrations by allowing close-to-complete action potentials to 
develop. The AP amplitude is slightly (~3 mV) higher at 6 mM than at 11 mM glucose in our simulation (Fig. 2), 
which is entirely due to an effect of glucose on SGLT2 in the model, suggesting that SGLT2 can act as a glucose 
sensor in A-cells. This assumption corresponds to the findings that whereas KATP channel closure is saturated at 
6 mM32, SGLT2 currents are not ref. 36.
Negligible reduction in cellular glucose uptake cannot explain dapagliflozin-induced stimulation 
of secretion. In the simulation in Fig. 2 we assumed that glucose acts in two ways on the A-cell action potential: 
via stimulation of the SGLT2 current (modeled as an increase of the parameter GSGLT2 in the model), and via glu-
cose metabolism, ATP production and closure of KATP-channels (modeled as a decrease of the parameter gKATP 
in the model). Dapagliflozin application was assumed to remove the SGLT2 current without affecting the KATP 
conductance. However, it has been suggested that the stimulatory effect of dapagliflozin is a result of reduced glu-
cose influx and metabolism when SGLT2-mediated glucose transport is blocked, which was speculated to open 
KATP channels and allow full action potentials to develop25.
We investigated theoretically whether the effect of dapagliflozin on glucose metabolism is feasible. Heimberg 
et al.37 found that, at 10 mM glucose, glucose enters islet non-B-cells (mostly A-cells) at a rate of approximately 
50 μ M/s via GLUT1 (50 μ mol per liter of cell volume). Glucose utilization was measured to be ~5 μ M/s. In steady 
state, the net influx balances consumptions, and thus GLUT1 must transport glucose outward at ~45 μ M/s, effec-
tively equilibrating extra- and intra-cellular glucose levels38. The SGLT2-mediated glucose fluxes predicted by 
our model are, based on a cell volume of 0.8 pL39,40, 0.8 and 1.7 μ M/s at 1 and 11 mM glucose, respectively. Thus, 
Figure 2. Model simulation of electrical activity. The glucose concentration was raised from 1 mM to 
6 mM and 11 mM, followed by simulated dapagliflozin application, as indicated. Simulations were performed 
by changing the glucose parameter in the SGLT2 submodel, GSGLT2, from 1 mM to 6 mM to 11 mM, and by 
lowering the KATP conductance from 0.15 to 0.115 nS to model the increase in glucose concentration to 6 
or 11 mM, since inhibition of KATP channel activity is maximal already at 6 mM glucose31. Dapagliflozin 
application was assumed to block all SGLT2 transporters, which was modeled by setting the parameter n = 0.
www.nature.com/scientificreports/
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GLUT1 transports glucose with rate at least an order of magnitude greater than our estimate of SGLT2-mediated 
uptake. Glucose uptake via GLUT1 is driven by the glucose concentration gradient across the membrane and 
is not the rate limiting step in A-cell glucose metabolism whereas glucose transport via SGLT2 is driven by the 
Na+ gradient across the cell membrane. Reduction in glucose inflow via SGLT2 will thus to a large extent be 
compensated for by an increased glucose net-inflow via GLUT1 (due to reduced outflow) as summarized by the 
steady-state relation Jin = (kout + kconsumption) × Gi.
As a consequence the ~3% reduction in glucose influx due to SGLT2 blockage will lower intracellular glucose 
levels (Gi) by a similar fraction, and therefore glucose consumption will decrease by only ~3%. Modest nonlin-
earities in glucose consumption such as for glucokinase38 will not change this conclusion. It is therefore highly 
unlikely that the reduction in glucose uptake due to SGLT2 inhibition reduces glucose metabolism and affects 
KATP-channel activity substantially. We therefore propose that SGLT2 inhibitors augment glucagon secretion 
principally because of direct effects on the membrane potential via interference with electrogenic Na+/glucose 
transport. Similar conclusions have been drawn from direct measurements of intracellular glucose in intestinal 
L-cells30. Finally, we note that our estimate of glucose uptake via SGLT2 is constrained by the electrophysiology 
in our model. If we increase the number of SGLT2 transporters in the model 5–10 fold to make SGLT2-mediated 
glucose uptake more comparable to GLUT1 transport, the model no longer produces action potentials resembling 
experimental recordings22 (Supplementary Fig. S4).
SGLT2 currents contribute to shape action potentials. Having clarified that dapagliflozin stimulates 
glucagon secretion at high glucose via a direct effect on action potential height, we investigated how SGLT2 cur-
rents contribute to shaping the A-cell action potential in our model. In response to depolarizations, the SGLT2 
current exhibits both a transient, outward component, and a sustained, inward component29. These components 
are also seen in our simulations of human A-cell electrical activity (Fig. 3).
At low glucose levels, action potentials are initiated when inward Na+ and Ca2+ currents depolarize the cell 
sufficiently to open high-voltage activated (HVA) L- and P/Q-type Ca2+ channels, which drive the upstroke of 
the action potential. During the upstroke, NaV channels inactivate, A-type K+ channel activate, and the transient, 
Figure 3. Ion currents during simulated action potentials during low glucose, high glucose, and high 
glucose in the presence of dapagliflozin. The upper panels show zooms on action potentials under the various 
conditions as indicated. The middle and lower panels show the simulated ion currents during the action 
potentials, as indicated in the legend. Note the different scales on the y-axes of the middle and lower panels.
www.nature.com/scientificreports/
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outward component of the SGLT2 current is evident. These events limit the height of the action potential, which 
is terminated when delayed-rectifier K+ currents activate. During the downstroke, the transient component of 
the SGLT2 current is inward and acts as a brake. The membrane potential drops to − 40 mV, which allows reacti-
vation of HVA Ca2+ channels, thus preparing the cell for the creation of the next action potential. Between action 
potentials, the SGLT2 current is slightly positive (outward).
At high glucose, or during tolbutamide application, the reduction in KATP channel activity has a number of 
effects. Most importantly, after an action potential, there is insufficient outward current to repolarize the mem-
brane potential sufficiently to reactivate Na+ and Ca2+ channels. The transient inward SGLT2 current acting as a 
brake during the downstroke aggravates the situation. Further, the sustained, inward component of the SGLT2 
current is more important than at low glucose concentration. As a result, the SGLT2 current is now inward 
between action potentials. Dapagliflozin application removes both the transient and sustained components of 
the SGLT2 current with converging effects. The removal of the sustained, inward component has the same effect 
as increasing the KATP-channel conductance. The lack of the transient, inward current permits K+ channels to 
repolarize the membrane potential more after an action potential. Both mechanisms allow reactivation of Na+ 
and Ca2+ channels and almost full action potential generation in the presence of dapagliflozin.
Discussion
Here we confirm clinical findings showing that SGLT2 inhibitors increase glucagon secretion at elevated glucose 
levels, and based on our theoretical investigations we propose that dapagliflozin activate pancreatic A-cells mainly 
via effects on electrical activity. In particular, we show that inhibition of SGLT2 with dapagliflozin doubles gluca-
gon secretion at high glucose concentrations (Fig. 1).
We calculated that SGLT2-mediated glucose transport contributes to only ~3% of total glucose uptake in 
A-cells. This result indicates that inhibition of SGLT2 leads to minimal changes in glucose metabolism and 
KATP-closure, and rather suggests that it is the removal of the SGLT2-associated electrical currents that influence 
electrical activity. Closure of KATP-channels reduces action potential height in mouse and human A-cells19,22,35, 
which we attribute to voltage-dependent inactivation of the Na+ and Ca2+ channels carrying the action potentials 
in this cell type. Our mathematical model of human A-cell electrophysiology predicts that SGLT2 inhibition can 
allow full-scale action potentials to develop when KATP-channel activity is reduced, i.e., at high glucose concen-
trations (Fig. 2). Since glucagon secretion depends strongly on the height of action potentials both in mice and 
human A-cells22,35, we suggest that the effects of SGLT2 inhibition on action potential height lie at the heart of 
dapagliflozin-stimulated glucagon secretion.
Our model simulations suggest that SGLT2 might be directly involved in glucose sensing in A-cells. Without 
changing the KATP conductance, an increase in the glucose concentration sensed by SGLT2 from 6 mM to 
11 mM results in a small reduction of AP height (Fig. 2). With other model parameters, which could repre-
sent a subset of A-cells, the simulated effect can be more pronounced, and AP may be present at 6 mM but fail 
to develop at 11 mM glucose (Supplementary Fig. 7), entirely because of SGLT2 glucose sensing. The further 
reduction of simulated AP height when increasing glucose levels from 6 to 11 mM may also underlie the fact that 
6 mM glucose inhibited glucagon secretion slightly less than 11 mM in our experiments on mouse islets (~24% 
vs. ~18% of control, Fig. 1). In the presence of dapagliflozin, SGLT2 can no longer act as a glucose sensor, and 
since KATP-conductance was assumed to be identical at 6 and 11 mM glucose, the model predicts that secretion is 
identical at 6 and 11 mM glucose in the presence of dapagliflozin, again in agreement with the experimental data 
(~32% vs. 30%, Fig. 1). In other words, the lack of a statistically significant effect of dapagliflozin at 6 mM glucose 
may be attributed to insufficient activation of the SGLT2-dependent glucose sensing system.
The SGLT2-associated current consists of two components, a transient and a sustained29. We find that the 
transient component acts a break during the downstroke of the action potentials (Fig. 3). The sustained, inward 
component tends to depolarize the cell, similarly to KATP-channel closure. Both components will tend to prevent 
repolarization and reactivation of Na+ and Ca2+ channels needed for full action potential generation, thus reduc-
ing the height of the action potentials. Removal of these inhibiting actions of the SGLT2-current by pharmaco-
logical inhibition will have the same effect as KATP-channel opening: reactivation of voltage-inactivated channels 
and increased action potential height (Fig. 4).
In human A-cells the resting conductance was ~120 pS no matter if the A-cells were exposed to 1 or 6–10 mM 
glucose, and addition of tolbutamide lead to a small decrease in resting conductance that did not reach signif-
icance22. This background conductance corresponds to just 6 open KATP-channels on average41. The failure of 
tolbutamide to further decrease the resting conductance indicates that other background conductances must be 
present. In rodent A-cells the resting conductance appears to be at least twice as large as in human A-cells and 
glucose-induced reduction of the resting conductance becomes detectable: Raising the glucose concentration 
from 1 to 6 mM reduced the resting conductance from 270 pS by 75 pS32 or ~25%. Almost the same reduction 
was obtained by adding tolbutamide in the presence of 1 mM glucose, whereas adding the drug in the presence 
of 6 mM had no further effect. Again, this indicates the presence of another, so far unknown background con-
ductance. In contrast to KATP-channels, SGLT2 is activated when the glucose concentration is increased and 
will thus partly obscure the glucose induced reduction in KATP-channel conductance, explaining the extremely 
small and in case of human A-cells, absence of glucose-induced detectable changes in resting conductance. In our 
model, the SGLT2 mediated component of the background conductance, calculated from simulated 10 mV depo-
larizations from − 70 mV, increases by ~7 pS (Supplementary Fig. 6) when glucose increases from 1 to 11 mM, an 
amount comparable to the average reduction in background conductance in response to tolbutamide22. Partial 
glucose sensing via SGLT2 thus fits well to the reported tiny or absent changes in background conductance upon 
glucose stimulation. Nevertheless, A-cells possess significant “spare” KATP-channel conductance as evidenced 
by diazoxide’s ability to overcome glucose-induced suppression of secretion. In mice A-cells 100 μ M diazoxide 
increases KATP-channel conductance to more than 2 nS compared to 0.27 nS observed at 1 mM glucose where 
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maximal secretion is obtained without pharmacological interference32. Contribution of SGLT2 to glucose sensing 
can thus explain how glucose can change the resting potential with changes in background conductance at or 
below the detection level. It would also be compatible with the observation that diazoxide can override glucose 
inhibition of glucagon secretion by opening of this spare KATP-conductance.
Overall, according to our model glucose dependence of glucagon secretion would mainly depend on the 
balance of background currents of which so far KATP-channels and now SGLT2 have been identified. Potentially 
other unidentified currents contribute in setting the resting membrane potential. Reported results on glucagon 
secretion vary considerably. For example sulfonylureas have been reported to increase, decrease and to have 
no effect on secretion15,42–44. Also results with the KATP-channel opener diazoxide vary, and the stimulatory 
effect of low dose diazoxide on secretion in the presence of high glucose could not be reproduced in a study 
by Cheng-Zue et al.15. Some of the reported differences are most likely due to experimental differences (static 
incubation vs perifusion, presence of amino acids, different animal strains etc.). However our model would offer 
explanation to some of the divergences: A bell shaped KATP-channel dependent secretion implies that the effect 
of KATP-channel modulators strongly depends on the metabolic state of the A-cell. In addition, ATP/ADP ratio 
sensing of the A-cell is complex and might differ between preparations. Although A- and B-cells express exactly 
the same KATP-channel subunits the ATP sensitivity is ~3 times higher in A-cells and dynamically regulated by 
insulin45 contributing to the high experimental variation. As a result, adding the same concentration of diazoxide 
might either increase or decrease the secretion response dependent on where the cells are on the bell shaped curve 
(Fig. 4).
Since the input resistance of the A-cell is very high, meaning the resting potential is set by very few open chan-
nels, already small changes in ion channel expression will have major effects, contributing to the variation seen 
in secretion measurements. Recently Bonner et al.25 demonstrated that progression towards diabetes in human 
and mice as well as culturing islets in high glucose for 24 h strongly increases SGLT2 expression. Apparently 
SGLT2 expression is under dynamic control, which will change the balance of the currents setting the resting 
membrane potential and contribute to the observed experimental variation. In the same study glucagon secretion 
was measured with similar results to ours, the main difference being that dapagliflozin amplified hormone release 
also at 1 mM glucose. This might be due to experimental variations as outlined above and possibly due to the high 
dapagliflozin concentration (12 μ M) used compared to our study (10 nM).
Clinical implications. Too high basal glucagon levels and the lost ability to respond to hypoglycemia with 
sufficient glucagon release are contributing factors to the diabetic phenotype2. Therefore, the potentiating effects 
of SGLT2 inhibition on glucagon secretion at elevated glucose levels might be viewed as problematic. Indeed, 
both dapagliflozin and empagliflozin, two chemically unrelated SGLT blockers, raise basal glucagon levels and 
hepatic glucose output. Even though it has not been demonstrated directly, it is fair to assume that the elevated 
glucagon levels cause the latter. However, since dapagliflozin lowers blood sugar levels via urinary glucose dis-
posal, simultaneous increased hepatic glucose output might even improve total glucose disposal and by that 
potentially induce weight loss.
According to our model glucagon secretion occurs in a certain window of resting potential and requires thus 
the right balance between KATP-channel and SGLT2 activity. Too strong depolarization will turn of secretion via 
inactivation of voltage-gated Na+ and Ca2+ channels, whereas strong hyperpolarization reduces secretion since 
the threshold for action potential generation will not be reached. Inhibiting SGLTs blocks the entry of positive 
Na+-ions through the transporter and has thus a hyperpolarizing effect and could therefore potentially compro-
mise glucagon secretion at low blood sugar levels. We found that glucagon secretion was virtually unaffected in 
mouse islets at 1 mM glucose, whereas there was a tendency towards lower secretion in the more limited human 
dataset. In contrast, Bonner et al.25 found that glucagon secretion was augmented by dapagliflozin at low glucose 
concentrations in human islets. Further studies are needed to clarify these aspects. Nonetheless, SGLT2 inhibition 
has only minor if any effect on the risk of hypoglycemia in clinical findings46–48.
Figure 4. Schematic representation of the control of glucagon secretion by KATP-conductance and SGLT2. 
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Material and Methods
Mice islet preperation and secretion measurements. Mice (C57black 12–20 weeks) were anesthetized 
(isoflurane) and killed by cervical dislocation. 0.9 U/ml collagenase P (cat no:1 213 873, Roche) was injected into 
the pancreatic duct, pancreata were removed and digested with collagenase for 17 min at 37 °C after which the 
samples were vigorously shaken. The digest was transferred into ice cold Hanks buffer with Ca2+ and Mg2+ and 
NaHCO3 (cat no 14025, Gibco), washed and islets hand-picked into RPMI-1640 media with Glutamax (Gibco 
72400-021), 10% FCS and 1% PEST at 37 °C and 5% CO2 and cultured for 48–72 hours before use. For glucagon 
secretion measurements, islets were washed twice in KRH buffer supplemented with 5.6 mM glucose and 0.1% 
BSA in petridishes and then preincubated in KRH 5.6 mM glucose and 0.1% BSA for 30 min at 37 °C, 5% CO2. After 
preincubation, islets were washed twice with 5.6 mM glucose in KRH and 0.1% BSA. 3 size matched islets/tube 
were incubated for 1 h at 37 °C in (KRH) supplemented with indicated constituents. After incubation 100 μ l/tube 
supernatant was harvested into a low binding eppendorf tube and frozen at − 80 °C. Glucagon was analyzed using 
a glucagon ELISA kit (Mercodia, Uppsala, Sweden). For each islet preparation 6–8 tubes were incubated under 
the same condition. Experimental procedures were approved by the Local Ethics Review Committee on Animal 
Experiments (Göteborg Region, Sweden) and all experiments were carried out in accordance with all relevant 
guidelines.
Human islet preparation and secretion measurements. Primary human islets were received from 
Prodo Laboratories Inc (Irvine, CA, USA) and kept in Prodo Islet Media Standard ((PIM(S))complete. For 
secretion measurements, islets were washed twice in 5.6 mM glucose, 0.1% BSA, KRH buffer. 3 islets/tube were 
incubated for 1 h at 37 °C in KRH buffer supplemented with indicated constituents and glucagon secretion was 
measured after 1 h incubation. Glucagon ELISA (Mercodia AB, Uppsala, Sweden), was run according to manu-
facturer’s protocol. For each islet preparation 6–8 tubes were incubated under the same condition.
Insphero islets. Re-aggregated human islets where ordered from Insphero and used according to the man-
ufacturer’s instructions. In short, one re-aggregated islet/well was cultured in GravtiyTRAPTM wells in Islet 
Microtissue Maintenance Medium until use. For glucagon secretion measurement islets were incubated for 2 h at 
the indicated glucose concentrations. Glucagon ELISA (Mercodia AB, Uppsala, Sweden), was run according to 
manufacturer’s protocol. For each islet preparation 6–8 wells were incubated under the same condition.
Mathematical modeling. A mathematical Hodgkin-Huxley-type model that describes electrical activity 
in human pancreatic A-cells was developed based on patch clamp data from human pancreatic A-cells22. The 
model includes ATP-sensitive K+ channels (KATP-channels), a passive leak current, voltage-gated Na+-, K+- and 
Ca2+-channels, and the electrogenic sodium glucose co-transporter SGLT2.
The evolution of the membrane potential V is driven by the contribution from the different currents,
= − + + + + + + + +dV/dt (I I I I I I I I I )/C , (1)KATP leak Na Kv KA CaT CaL CaPQ SGLT2 m
where Cm is the cell membrane capacitance. Voltage-gated membrane currents are modeled as
= −I g m h (V V ), (2)X X X
nX
X X
where X stands for the channel type, VX is the associated reversal potential, gX the maximal whole-cell channel 
conductance, and mX and hX describe activation and inactivation of the channel, respectively.
Activation (similarly inactivation) is described by
= τ∞ –dm /dt (m (V) m )/ , (3)X X, X mX
where mX,∞(V) is the steady-state voltage-dependent activation function, and τ mX is the time-constant of activa-
tion, which in some cases depends on the membrane potential.
Steady-state voltage-dependent activation (inactivation) functions were described by the Boltzmann equation
= + − .∞
−m (V) [1 exp((V V )/S )] (4)X, mX mX
1
SGLT2 was modeled as a six-state model with the associated current related to movements of charged residues 
of the transporters as in the SGLT1 model of Parent et al.27, with modification to account for species differences28, 
and differences between SGLT1 and SGLT229.
Details of the individual currents and parameters can be found in the Supplementary Material. Simulations 
were performed in MATLAB™ (R2014a, MathWorks Inc., Natick, MA, USA) using the ode15s solver. Computer 
code is available as Supplementary Material.
Statistics. Glucagon secretion measurements were highly non-normal distributed and were therefore 
log-transformed to improve normality. The log-transformed data were fitted to a linear statistical mixed-effects 
model with low/high glucose and absence/presence of dapagliflozin as covariates including an interaction term 
(fixed effects) and individual/animal as random effect to take into account the fact that measurements performed 
on islet preparations from the same individual/animal are correlated. P-values were calculated from two-sided 
t-tests, and considered significant at the 0.05 level. All analyses were performed in R version 3.0.249 using the lm 
and lme (from the nlme package50) functions as appropriate.
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